1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Chugai In-Licenses Anti-Tl1a Antibody Rg6631

09 Aug 2024
Admin
News Article

Chugai In-Licenses Anti-Tl1a Antibody Rg6631

Chugai in-licenses anti-TL1A antibody RG6631 for the intractable diseases ulcerative colitis and Crohn’s disease

Overview

Chugai Pharmaceutical Co., Ltd. announced that it has concluded a license agreement with F. Hoffmann-La Roche Ltd for RG6631, the anti-TL1A antibody, currently in development for ulcerative colitis and Crohn’s disease. Under the license agreement between Roche and Chugai, Chugai obtained exclusive rights for the development and marketing of RG6631 in Japan. Roche will receive an upfront fee and milestone payments.

Words from CEO: Chugai

“Ulcerative colitis and Crohn’s disease are intractable conditions characterized by cycles of remission and relapse. The recurring symptoms such as diarrhoea and abdominal pain often restrict daily life, requiring long-term hospital visits, and the risk of developing colon cancer increases as the disease progresses. In addition, treatment methods to maintain remission have not been sufficiently established, and there remains a significant unmet need. Chugai will work closely with Roche to bring RG6631 to patients with Ulcerative colitis and Crohn’s disease as soon as possible,” said Chugai’s president and CEO, Dr. Osamu Okuda.

About RG6631

RG6631 is a potential first-in-class therapy targeting TL1A, is expected to demonstrate high efficacy by simultaneously suppressing inflammation and fibrosis, and has the potential to be applied in multiple other diseases.
In the global phase IIb study (TUSCANY-2) in patients with moderate to severe ulcerative colitis, treatment with RG6631 showed improvement in multiple endpoints including clinical remission in both the induction and maintenance periods.
Roche plans to initiate a phase III study by the end of 2024. The phase II study is ongoing for moderate to severe Crohn’s disease.

Chugai will continue to effectively utilize the research and development resources of the Roche Group to find innovative new drugs so as to satisfy unmet medical needs.

Inflammatory Bowel Diseases

Ulcerative colitis and Crohn’s disease are inflammatory bowel diseases, which refer to chronic or relapsing-remitting inflammatory disorders of the intestinal tract.
Symptoms include abdominal pain, frequent bowel movements, diarrhoea, weight loss and fatigue.
Approximately 80% of patients do not achieve sustained remission, with cycles of relapse and remission being common.
Loss of response to medications can also occur over time, and there remains a need for new therapies, particularly for small bowel and perianal disease.

About Ulcerative Colitis

Ulcerative colitis has a peak onset in the 20s and is a condition in which erosions and ulcers form in the mucosa (innermost layer) of the large intestine.
Lesions tend to spread continuously from the rectum and ascend orally, extending to the entire colon at maximum.
It is one of the designated intractable diseases in Japan (designated intractable disease 97), and the number of medical recipient certificate holders for this disease was 141,387 at the end of year 2022.

About Crohn’s Disease

Crohn’s disease is mainly seen in younger age groups and is characterized by discontinuous lesions (the presence of normal areas between lesions).
Inflammation and ulcers (mucosal defects) primarily affect the small and large intestines, with the terminal ileum being a common site, but can occur in any part of the digestive tract from the mouth to the anus.
It is one of the designated intractable diseases in Japan (designated intractable disease 96), and the number of medical recipient certificate holders for this disease was 50,184 at the end of year 2022.